Damora Therapeutics is trading 6.1% down now at $27.39, with the move appearing primarily sector-driven as healthcare stocks face pressure amid worsening insurance-coverage concerns.
- The decline extends from the September 8 close of $29.17.
- No major company-specific announcement dated September 9 was identified; the latest release concerned inducement grants announced September 3.
- Broader risk-off sentiment from geopolitical tensions, higher oil prices, and rate expectations is adding pressure.